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INTRODUCTION
Since 1983 when Helicobacter pylori was first cultured, H. 
pylori infection is known as the main cause of chronic antral 
gastritis, peptic ulcer disease, low grade gastric mucosa-asso-
ciated lymphoid tissue lymphoma (MALT lymphoma) and 
gastric cancer.
1 H. pylori eradication therapy is quite effective 
for the protection of peptic ulcer disease and the treatment of 
low grade gastric MALT lymphoma.
A triple therapy using proton pump inhibitor (PPI) and 2 
antibiotics or a quadruple therapy which includes bismuth to 
the triple therapy are currently recognized as the most effec-
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tive eradication therapies and are widely used.
2
The eradication rates of these standard regimens, however, 
are decreasing due to the increased antibiotic resistance, as 
with the eradication rates reported in South Korea decreasing 
to 75-85%, which is of great concern.
3,4
Triple therapies including quinolone or rifabutin could be 
used when the first and second eradication therapies were fa-
iled.
5,6 These therapies, however, have various limitations such 
as their cost-effectiveness or resistance rates, and there is no 
definite standard regimen for a 3rd line rescue therapy.
Recent studies reported that a dual therapy consisting of 
high-dose PPI and amoxicillin provided significant eradica-
tion rates in patients who did not respond to the prior H. pylori 
treatments, suggesting that this new dual therapy could be pro-
mising as a rescue therapy.
7,8
We evaluated the eradication rate, side effects and compli-
ance of the esomeprazole and amoxicillin dual therapy as a 
3rd line therapy in patients of H. pylori infection who did not 
respond to a 1st and 2nd line eradication therapy, in order to 
determine its availability as a rescue therapy.
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MATERIALS AND METHODS
Patient population
This trial was performed in patients who experienced two 
consecutive eradication failures, among those who visited 
Seoul National University Bundang Hospital and were diag-
nosed as H. pylori infection between September and Decem-
ber of 2010. The patients who received the dual therapy as a 
3rd line therapy and were available for the follow up were in-
cluded in this retrospective analysis. Patients with a history 
of esophagus or gastric surgery or receiving a treatment for ch-
ronic disease other than hypertension or diabetes mellitus 
were excluded from the study.
Study design
H. pylori test
13C urea breath tests (UBT) were performed each after the 
first and second eradication therapy, in order to confirm the 
H. pylori status, by measuring 
13CO2 before and 20 minutes 
after the administration of 
13C urea. A patient was determined 
positive when the level had changed 2.5% or more. The third 
eradication regimen was provided when the UBT result was 
confirmed positive after the second therapy. UBT was repeat-
ed 6 weeks later to confirm whether H. pylori were eradicated.
Treatment
The dual therapy consisting of esomeprazole and amoxicil-
lin was prescribed to patients who were determined positive 
in UBT after the first and second eradication therapies. Presc-
ription record was analyzed to identify the drugs prescribed 
for the first and second therapies, and patients were inter-
viewed to confirm their compliance to these drugs. Patients 
received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 
mg, b.i.d.) for 14 days as a third eradication regimen, which 
were to be taken at least 30 minutes before the breakfast and 
dinner when the stomach was empty. Compliance and side ef-
fects were determined by interview and self-reported symp-
toms during the visit 6 weeks after completing the eradication 
regimen. Compliance was deemed good when a patient took 
more than 85% of the prescribed drugs. The enrolled patients 
were informed about the possible side effects associated with 
the esomeprazole/amoxicillin dual therapy and the possibility 
of eradication failure. The patients provided written inform-
ed consent before starting the treatment.
Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used 
for statistical analysis, with frequencies expressed by percent-
age (%). Chi-square test or Fisher’s exact test were performed, 
and p-values of less than 0.05 were considered to indicate st-
atistical significance.
RESULTS
Patients
Overall 21 patients were enrolled in this study, of which 11 
were male and 10 were female (sex ratio, 1.1:1). The mean age 
of the patients were 59 years (range, 38 to 79). Some of the pa-
tients had the history of alcohol consumption (n=7, 33.3%), 
smoking (n=4, 19.0%), or nonsteroidal anti-inflammatory 
drug (NSAID) use (n=6, 28.6%). Six patients (28.6%) had the 
history of peptic ulcer disease, 13 patients (61.9%) functional 
dyspepsia, and 2 patients (9.5%) gastric adenoma. Every pa-
tient received a PPI-based triple therapy for the first eradica-
tion regimen. For the second therapy, 8 patients (38%) receiv-
ed a bismuth-based quadruple therapy and 13 patients (62%) 
received a moxifloxacin-based triple therapy (Table 1).
H. pylori eradication rate and side effects
Fourteen patients of the overall 21 patients were confirmed 
negative from the UBT performed 6 weeks after completing 
the 2-week esomeprazole and amoxicillin period, indicating 
66.7% (95% confidence interval, 45-87%) of eradication rate.
All 21 patients took more than 85% of the prescribed drugs. 
Three patients (14.3%) reported side effects, and the most com-
mon symptoms were mild nausea and epigastric discomfort. 
Table 1. Baseline Characteristics of the Patients
Variables      Patients
No. of patients 21
Mean age  (range), yr 59 (38-79)
Gender,  M/F 11:10
Indication for treatment
   Peptic ulcer disease, No. (%) 06 (28.6)
   Non-ulcer dyspepsia, No. (%) 13 (61.9)
   Gastric adenoma, No. (%) 02 (9.5)
History of alcohol drinking, No. (%) 07 (33.3)
History of smoking, No. (%) 04 (19.0)
History of using NSAID, No. (%) 06 (28.6)
History of using antibiotics, No. (%) 00 (0)
Previously used 1st line regimens
   PPI-AC
a), No. (%)
Previously used 2nd line regimens
   PPI-BMT
b), No. (%)
   PPI-MA
c), No. (%)
21 (100)
08 (38)
13 (62)
NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump 
inhibitor.
a)AC, amoxicillin+clarithromycin; 
b)BMT, bisthmus+metronidazol
e+tetracycline; 
c)MA, moxifloxacin+amoxicillin.HK Park et al. 
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No patient discontinued the trial due to a test drug-related side 
effect (Table 2).
The subgroup of patients who received bismuth-based qu-
adruple therapy showed higher eradication rate than patients 
who received moxifloxacin-based triple therapy (87.5% vs. 
53.8%), but the difference was not statistically significant (Ta-
ble 3).
There was no significant difference in the eradication rates by 
gender, underlying disease, smoking status, or NSAID use.
DISCUSSION
According to the report by Yim et al.,
9 the prevalence of H. 
pylori infection in South Korea is still considerably high at 
59.6%, although the figure has been dropping. While the num-
ber of H. pylori eradication therapy cases has increased a lot 
thanks to the universal screening esophagogastroduodenos-
copy and greater interest in gastrointestinal disease, the suc-
cess rate of eradication is continuously decreasing, which is 
of great concern.
9
Even the currently recognized and widely used standard 
triple and quadruple eradication therapies show eradication 
failure rate as much as 20%.
10 More and more patients, there-
fore, are found still H. pylori positive even after the second 
eradication therapy, but we still don’t have a definite guide-
line for a 3rd line or more rescue therapy.
As the antibiotic resistance and the number of patients 
who do not respond to the 1st and 2nd line eradication thera-
py increases, drugs such as levofloxacin, moxifloxacin, and 
rifabutin are becoming subjects of studies as a 3rd line thera-
py. Levofloxacin and moxifloxacin, which are both broad spec-
trum fluoroquinolones, draw much attention for being high-
ly active, easy to take, and less likely to induce side effects.
11,12 
It seems prudent, though, to consider carefully before using 
these drugs widely as a treatment for H. pylori infection, since 
resistance to fluoroquinolones is rising rapidly due to the in-
creased use of antibiotics.
13
Rifabutin is studied mostly as a rescue therapy for patients 
who failed the first or second eradication therapy, with eradic-
ation rates reported around 60-79%.
14,15 There is no resistant 
H. pylori strain reported yet against rifabutin,
16 which is why 
it might be effective as a rescue therapy for patients who did 
not respond to the existing eradication therapy. Rifabutin, how-
ever, is very expensive and possible to induce serious side ef-
fects including bone marrow suppression,
17 and in some areas 
where prevalence of tuberculosis is high, such as in South Ko-
rea, it is highly possible to induce drug-resistant tuberculosis.
The dual therapy consisting of high-dose PPI and amoxi-
cillin was first introduced in mid-1990s as a first-line regimen 
against H. pylori,
18,19 which was discontinued later due to its lo-
wer eradication rate than triple therapies.
20 When combined 
with PPI, however, amoxicillin concentration is increased 
within gastric mucosa, thanks to the inhibition of gastric acid 
by PPI, and the minimal inhibitory concentrations (MIC) 
against H. pylori becomes greatly reduced, which makes it 
appropriate for eradication regimen.
21,22 Also, amoxicillin sh-
ows high eradication rate when used as a third-line therapy, 
since it induces less antibiotic resistance even after used as the 
first and second-line regimen.
23
Recently, Miehlke et al.
7 used high-dose PPI/amoxicillin 
dual therapy as a 3rd line rescue therapy for patients with re-
sistance to metronidazole and clarithromycin, and confirmed 
the eradication rate as high as 75.6% with minimal side effects, 
suggesting that this regimen could be a good alternative for a 
rescue therapy.
The most important factors in H. pylori eradication are 
drug sensitivity and compliance.
24,25 PPI/amoxicillin regimen 
has strong advantage with this regard, since it induces less 
side effects than other 3rd line regimen, and it requires pa-
tients to take less number of drugs, contributing to the im-
proved patient compliance. Especially older patients are in-
fluenced more by regimen and side effects in their compliance 
to medications. Patients in this study were comprised mostly 
of older patients with mean age of 59, ranging up to 79 years. 
It was conceivable, accordingly, that this simple PPI dual th-
erapy would be more effective in this patient population than 
other complicated, side effect-inducing triple therapies. We 
tried 3rd line regimen using esomeprazole and amoxicillin, 
which showed 100% of compliance in all 21 patients. Three 
out of 21 patients reported only minor side effects, such as 
nausea and epigastric discomfort, and these side effects did 
not affect the medication.
Table 2. Overview of Treatment Efficacy on Evaluable Patients 
and Side Effects
H. pylori eradicated
    No. (%) 14/21 (66.7)
    95% CI , %
Compliance, No. (%)
Side effects, No. (%)
46-87
21/21 (100).
03/21 (14.3)
CI, confidence interval.
Table 3. Eradication Rate According to Previous 2nd Line Regimen
H. pylori 
eradicated,
No. (%)
p-value
a)
Bisthmus based quadruple therapy 
    (n=8) 7 (87.5)
Moxifloxacin based triple therapy
    (n=13) 7 (53.8) 0.174
a)p-value was calculated using Fisher’s exact test.36  Clin Endosc 2011;44:33-37
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The overall eradication rate of this 2-week esomeprazole 
and amoxicillin regimen was 66.7%, which was less than ex-
pected for a 3rd line eradication therapy. Unlike previous dual 
therapy studies used 3 or 4 times higher dose of PPI than st-
andard dose,
7,8 this study used 80 mg of esomeprazole which 
is twice the standard dose. In South Korea, it is very difficult 
to use 4 times higher dose of PPI than standard dose, due to 
the limited medical insurance coverage. The study also has 
limitation that the sample size is not large enough to evaluate 
the effectiveness of PPI/amoxicillin dual therapy. Further pro-
spective studies are needed, therefore, using various dose of 
PPI in larger patient populations.
Most conventional PPI/amoxicillin dual therapies used om-
eprazole for PPI, supposedly because there were only limited 
PPIs at the time. This study used esomeprazole, one of the 
most commonly used PPIs at the moment. A meta-analysis 
study on eradication rate differences based on the eradication 
effect of omeprazole did not show any significant eradication 
rate difference between PPIs,
26 which was similar in studies 
of South Korea.
27 It is suggested, therefore, that the eradica-
tion rate reported in this study was not influenced much by 
the use of esomeprazole instead of omeprazole.
When classified according to the 2nd line regimen, the sub-
group of bismuth-based quadruple therapy was found to 
show higher eradication rate than the subgroup of moxiflox-
acin-based triple therapy (87.5% vs. 53.8%). Although the dif-
ference was not statistically significant, given that amoxicillin 
was included in moxifloxacin-based triple therapy, repeated 
use of amoxicillin might be associated with the reduced eradic-
ation rate. It would be important, therefore, to confirm what 
prior regimen was used for a patient, before considering PPI/
amoxicillin dual therapy as a 3rd line regimen. H. pylori cul-
ture and drug sensitivity test is required, in this regard, for 
additional analysis, but the drug sensitivity test was not per-
formed in this study.
Antibiotic sensitivity is an important factor in H. pylori 
eradication. A drug sensitivity test is recommended before 
selecting a 3rd line regimen, because a patient might have al-
ready used various antibiotics if the 2nd line therapy was 
failed.
2,28 The patients involved in this study also had already 
used 3 or more antibiotics through 1st and 2nd therapy. This 
study, however, did not perform drug sensitivity test, which 
could limit the result of this study.
Nevertheless, there is much debate on the necessity of drug 
sensitivity test by H. pylori culture. H. pylori culture is quite 
difficult, expensive, and time-consuming to perform, and it 
requires endoscopy to collect samples, further limiting rou-
tine culture test.
29 In addition, some studies that performed 
drug sensitivity test against H. pylori before selecting a 3rd 
line regimen showed rather disappointing eradication rate of 
less than 60%, raising question to its practicality.
30,31
In conclusion, the result of this study proved that a 2-week 
esomeprazole/amoxicillin dual therapy produces rather limit-
ed but moderate 67% eradication rate. This dual therapy sh-
owed improved patient compliance and minor side effects, 
making it a promising empirical 3rd line rescue therapy for 
patients unsuitable for multiple drug use or with high risk of 
side effects. This finding warrants further study in a larger sam-
ple, since this study is limited by its small sample size. Given 
that the frequency of H. pylori eradication therapy would in-
crease in the future, continuous study on H. pylori infection 
rescue therapy is required.
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